Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BTRX-246040 in Major Depressive Disorder
NCT03193398Phase 2Completed
- Sponsor
- BlackThorn Therapeutics
- Start
- Jun 2017
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing BTRX-246040 with Placebo (2 arms). Primary endpoint: Montgomery-Asberg Depression Rating Scale Total Score at 8 weeks. Started Jun 2017; status: completed.
02
Drugs
LY2940094
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03193398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03193398.